InMed Phase 2 Trials for EB Cannabinol Treatment

Epidermolysis bullosa (EB) is an extremely uncommon genetic skin condition. InMed Pharmaceuticals, a pioneer in the pharmaceutical study, discovery, and production of rare cannabinoids and cannabinoid analogs, has revealed that they have finished registrations for its stage 2 clinical investigation using CBN cream for the treatment of individuals with this disease.

During research undertaken prior to the clinical trial, INM-755 (cannabinol) cream was shown to possibly repair skin structure and assist a segment of those with EB Simplex in experiencing less discomfort, swelling, wound recovery, and irritation.

The outcomes from the clinical trials in question are anticipated to be announced at the start of Q3 this year.

CEO of ImMed, Eric Adams, explained that “cannabinoids hold tremendous therapeutic potential, however, to date there have been limited evidence-based studies investigating their effects.”

InMed’s SVP of Clinical and Regulatory Affairs, Alexandra Mancini explained that they have “enrolled 19 patients in InMed’s trial of INM-755 cannabinol cream for EB, a rare disease that has major unmet medical needs.” And are “hopeful results from this Phase 2 study will provide an indication that INM-755 CBN cream may provide symptomatic relief for EB patients.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.